Abstract

Background: Since few decade stem cell research is being more crucial as it has the ability to renew their own population and to differentiate into specialized population of cells. To overcome the immune rejection, ethical issue of embryonic stem cells, and for more practical point of view, patients own body cells be reprogrammed to assume a stem cell like state called induced pluripotent cells (iPSCs) which maintain all the essential properties of embryonic stem cells. Aim: The use of iPS cells for differentiating into various cell type of body and derived differentiate cells to provide personalized cells for cell based therapy is the great aim and it opened the new avenue for regenerative medicine. Objectives: The capability of induced pluripotent stem cells (iPSC) is tremendous as it infinitely divided and differentiated into many different cell types. Hence objective is to use iPSCs to model several diseases to unravel the mechanism of alterations in these diseases. Material: Various approaches were used to induce iPSCs such as delivering reprogramming factors (Oct4, Sox2, Klf4 & c-Myc) into somatic cells or by using a cocktail of small-molecule compounds that modulate various signaling pathways. Result: The tissue of patients are used to generate immune-matched supply of pluripotent stem cells to test or screen the drug and study the specific cause for that disease in patient specific way. The stem cell research including iPS cells has received a significant amount of public attention for neurodegenerative diseases, diabetics and other tissue specific diseases. Conclusion: Great benefits are expected in this field as researchers take advantage of the tremendous potential regenerative properties of induced pluripotent stem cells for promising therapeutic applications, which is described in this article. DOI: 10.21088/ijnns.0975.0223.17125.5 Author’

• 1.   Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-872.
• 2.   Sachinidis A., Albrecht W., Nell P., Cherianidou A., Hewitt N.J., Edlund K., Hengstler J.G. Road Map for Development of Stem Cell-Based Alternative Test Methods. Trends Mol Med. 2019; 25(6): 470-481.
• 3.   Zaehres, H., Scholer, H.R. Induction of pluripotency: from mouse to human. Cell. 2007; 131: 834-835.
• 4.   Tsai, S.Y., Clavel, C., Kim, S., Ang, Y.S., Grisanti, L., Lee, D.F., Kelley, K., Rendl, M. Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem cells. Stem Cells. 2010; 28: 221-228
• 5.   Kondo Y., Toyoda T., Inagaki N., Osafune K. iPSC technology-based regenerative therapy for diabetes. J Diabetes Investig. 2018; 9(2): 234-243.
• 6.   Bonaventura G., Iemmolo R., Attaguile G.A., La Cognata V, Pistone BS, Raudino G, D’Agata V, Cantarella G, Barcellona M.L., Cavallaro S. iPSCs: A Preclinical Drug Research Tool for Neurological Disorders. Int J Mol Sci. 2021; 22(9): 4596.
• 7.   Li J., Hua Y., Miyagawa S., Zhang J., Li L., Liu L., Sawa Y. hiPSC-Derived Cardiac Tissue for Disease Modeling and Drug Discovery. Int J Mol Sci. 2020; 21(23): 8893.
• 8.   Kistamás K., Lamberto F., Vaiciuleviciute R., Leal F., Muenthaisong S., Marte L., SubíasBeltrán P., Alaburda A., Arvanitis D.N., Zana M., Costa P.F., Bernotiene E., Bergaud C., Dinnyés A. The Current State of Realistic Heart Models for Disease Modelling and Cardiotoxicity. Int J Mol Sci. 2024; 25(17): 9186.
• 9.   Dekoninck S., Blanpain C. Stem cell dynamics, migration and plasticity during wound healing. Nat Cell Biol. 2019; 21(1): 18–24.
• 10.   Kretzschmar K., Clevers H. Organoids: Modeling Development and the Stem Cell Niche in a Dish. Dev Cell 2016; 38: 590-600.
• 11.   Andrews M.G., Kriegstein A.R. Challenges of Organoid Research. Annu Rev Neurosci 2022; 45: 23-39.
• 12.   Zhang T., Qian C. Application Prospect of Induced Pluripotent Stem Cells in Organoids and Cell Therapy. 2024; 25 (5): 2680.
• 13.   Warren, L., Manos, P.D., Ahfeldt, T., Loh, Y.H., Li, H., Lau, F., Ebina, W., Mandal, PK, Smith, ZD, Meissner, A, Daley, G.Q., Brack, A.S., Collins, J.J., Cowan, C., Schlaeger, T.M., Rossi, D.J. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010; 7: 618-630.
• 14.   Yakubov, E., Rechavi, G., Rozenblatt, S., Givol, D . Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four scription factors. Biochem. Biophys. Res. Commun. 2010; 394: 189-193.
• 15.   Egashira T., Yuasa S., Fukuda K. Novel insights into disease modeling using induced pluripotent stem cells. Biol Pharm Bull 2013; 36: 182– 188.
• 16.   Jang, J., Yoo, J.E., Lee, J.A., Lee, D.R., Kim, J.Y., Huh, Y.J., Kim, D.S., Park, C.Y., Hwang, D.Y., Kim, H.S., Kang, H.C., Kim, D.W. Diseasespecific induced pluripotent stem cells: a platform for human disease modeling and drug discovery. Exp. Mol. Med. 2012; 44: 202- 213.
• 17.   Kondo, T., et al., Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell. 2013; 12(4): 487-96
• 18.   Chang K.H., Lee-Chen G.J., Huang C.C., Lin J.L., Chen Y.J., Wei P.C., Lo Y.S., Yao C.F., Kuo M.W., Chen C.M. Modeling Alzheimer’s Disease by Induced Pluripotent Stem Cells Carrying APP D678H Mutation. Mol Neurobiol. 2019; 56(6): 3972-3983.
• 19.   Ochalek A., Mihalik B. et al., Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation. Alzheimers Res Ther. 2017;9(1):90.
• 21.   Hayes M., Zavazava N. Strategies to generate induced pluripotent stem cells. Methods Mol Biol. 2013; 1029: 77-92.
• 22.   Wen, Y., Chen, B., Ildstad, ST. Stem cell-based strategies for the treatment of type 1 diabetes mellitus. Expert. Opin. Biol. Ther. 2011; 11: 41- 53.
• 23.   Bell, K.F., Hardingham, GE. The influence of synaptic activity on neuronal health. Curr. Opin. Neurobiol. 2011; 21: 299-305.

Data Sharing Statement

Funding